Transcatheter Mitral Valve Repair: Is there a Future?

  • Apostolos Tzikas Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
  • Nicolo Piazza Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
  • Patrick W Serruys Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
  • Peter P.T. de Jaegere Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands

Abstract

Mitral regurgitation (MR) is a common disease in developed countries, affecting an estimated 9.3% of the population aged ≥75 years. Although surgical valve repair or replacement is currently the “gold standard” treatment for severe symptomatic MR, almost one-half of the patients are denied surgery. These are usually older patients with moderate left ventricular dysfunction and several non-cardiac co-morbidities. The aim of transcatheter mitral valve repair is to provide a treatment that is at least as effective as conventional valve surgery, and is associated with less morbidity and mortality. Currently an important number of devices are under evaluation, and can be categorized according to the treatment strategy.... (excerpt)

Author Biography

Apostolos Tzikas, Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Specialty: Cardiology
Section
Athens Cardiology Update 2010